Abstract 10P
Background
Endometrial cancer (EC) patients harbouring POLE mutations have been shown exceptionally good survival outcomes allowing de-escalation of adjuvant treatment. POLE encodes for the Pol ε catalytic subunit capable of correcting DNA synthesis errors; pathogenic mutations within the exonuclease domain (EDM) result in an ultramutated phenotype. So far, 11 POLE EDM variants have been recognized as hotspot mutations. Given the increasing availability in clinical practice of comprehensive genome profiling (CGP), the interpretation of non-hotspot EDM variants has become challenging.
Methods
EC patients enrolled in a CGP programme at Fondazione Policlinico Universitario Agostino Gemelli IRCCS were profiled using TSO500HT. VCF files containing identified variants were analyzed developing an in-house Python and R language script. The following parameters including the frequency of C > A, C > G, T > G substitutions, tumor mutational burden (TMB), the frequency of indels, and the presence of recurrent mutations were evaluated and a score to interpret POLE mutations was recalibrated from Castillo et al. published score on TCGA data.
Results
From January 2022 to May 2023, CGP was available for 392 EC patients. New thresholds for the frequency of C > A, C > G, T > G substitutions and indels were calculated based on the mean of the median values of each parameter comparing POLE EDM hotspots vs POLE benign variants and wild type (WT) cases. Overall, the score correctly identified the POLE hotspot mutations in 40/42 patients. One of the 2 misclassified cases was a FIGO stage IIIC1 case, displaying a TMB of 36.5; the other displayed a TMB of 87. 5 POLE EDM non-hotspot variants were identified (D287E, N363K, T278M, D262H, R375Q) and none of them reached a score ≥ 4. None of these cases displayed a COSMIC signature 10 as expected for POLE EDM hotspot cases. Among the co-mutations, ATM and APC variants were reported to be differentially expressed among POLE EDM hotspots and POLE EDM non-hotspots vs POLE benign and WT cases (ATM: 60%, 60% vs 10%, 11%; APC: 35%, 20% vs 3.8% and 0% respectively).
Conclusions
We adapted Castillo’s TCGA-based POLE score to a CGP assay. This approach could be helpful to interpret POLE EDM non hotspots variants emerging from wide routine genomic characterization.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
C. Nero: Financial Interests, Personal, Other, Travel grant: Illumina. D. Lorusso: Financial Interests, Institutional, Funding: Clovis, GSK, MSD; Financial Interests, Personal, Funding: AstraZeneca, Clovis Oncology, MSD; Non-Financial Interests, Personal, Advisory Board: GCIG. G. Scambia: Non-Financial Interests, Personal, Advisory Board: Tesaro, Johnson & Johnson; Financial Interests, Institutional, Funding: MSD, Clovis Oncology. All other authors have declared no conflicts of interest.
Resources from the same session
11P - Reconstructing tumour evolution of single cells using both somatic mutations and copy-number alterations
Presenter: Rija Zaidi
Session: Cocktail & Poster Display session
Resources:
Abstract
12P - Swiss-PO: Molecular modelling for precision oncology
Presenter: Fanny Krebs
Session: Cocktail & Poster Display session
Resources:
Abstract
13P - A novel algorithm for predicting variant detectability in oncogenomic analysis
Presenter: Alper Akkuş
Session: Cocktail & Poster Display session
Resources:
Abstract
14P - expHRD: An algorithm for the transcriptome-based estimation of homologous recombination deficiency score
Presenter: Jin-Ku Lee
Session: Cocktail & Poster Display session
Resources:
Abstract
15P - ClinBioNGS: An integrated clinical bioinformatics pipeline for the analysis of somatic NGS cancer panels
Presenter: Xavier Sole
Session: Cocktail & Poster Display session
Resources:
Abstract
16P - Investigation of c-MYC role in DNA-PK-mediated activation of STING pathway in SCLC
Presenter: Caterina de Rosa
Session: Cocktail & Poster Display session
Resources:
Abstract
17P - NRF2 activation promotes HER2-targeted tolerance and resistance in oesophageal adenocarcinoma through metabolic reprogramming to glutathione
Presenter: Wei Zhang
Session: Cocktail & Poster Display session
Resources:
Abstract
18P - AURKB inhibition radiosensitises NSCLC by altering mitotic fate
Presenter: Kathryn Egerton
Session: Cocktail & Poster Display session
Resources:
Abstract
19P - Stratified control study on neuroendocrine differentiation and potential clinical markers in patients with limited-stage small-cell lung cancer
Presenter: Li Liu
Session: Cocktail & Poster Display session
Resources:
Abstract
20P - Effects of <italic>Apis dorsata</italic> honey on the expression of selected CYP450, pro-apoptotic, and anti-apoptotic genes during induced cytotoxicity in cyclophosphamide-treated human lung carcinoma (A549) cells
Presenter: Jose Kenneth Narag
Session: Cocktail & Poster Display session
Resources:
Abstract